Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05649098 · ClinicalTrials.gov registry record · Early Phase 1
Repurposing Dupilumab for Management of Pruritic Genetic Inflammatory Skin Disorders
A Early Phase 1 study of Skin Diseases, sponsored by Northwestern University.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT05649098 is a Early Phase 1 study of Skin Diseases that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 30 participants, below the 208-participant average among 14 other Skin Diseases trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05649098, a Early Phase 1 study of Skin Diseases, is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Severe itch is a common symptom of many genetic skin disorders and leads to a negative impact on patient quality of life. The investigators hypothesize that: a) intervention with dupilumab will improve itch in patients with pruritic genetic inflammatory skin disorders, even those not recognized to be Th2-driven; and b) the administration of dupilumab will be well-tolerated, regardless of underlying genetic skin disorder. The total clinical study duration will be 26 months (104 Weeks). The treatment period will include a 16-week open-label phase and a 20-month long-term extension phase for those who qualify and wish to continue.
Conditions Studied
Interventions
- DRUG Dupilumab
Study Locations (1)
Illinois
- Ann & Robert H. Lurie Children's Hospital of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2023-06-12 |
| Est. Completion | 2026-06-01 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05649098
The ClinicalTrials.gov registry entry for NCT05649098 describes a study currently listed as recruiting, categorized as Early Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 208-participant average among 14 other Skin Diseases trials with a reported enrollment target (86% lower). The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Skin Diseases appearing as the primary indexed condition, and to 1 intervention - of which Dupilumab is the first listed.
NCT05649098 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT05649098 about?
NCT05649098 is a clinical study titled "Repurposing Dupilumab for Management of Pruritic Genetic Inflammatory Skin Disorders". Severe itch is a common symptom of many genetic skin disorders and leads to a negative impact on patient quality of life. The investigators hypothesize that: a) intervention with dupilumab will improve itch in patients with pruritic genetic inflammatory skin disorders, even those not recognized to b...
What is the current status of trial NCT05649098?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 30 participants. The study started on 2023-06-12. Estimated completion is 2026-06-01.
What conditions does trial NCT05649098 study?
This clinical trial studies the following conditions: Skin Diseases.
What interventions are being tested in trial NCT05649098?
The interventions under investigation include: Dupilumab (DRUG).
Who is sponsoring clinical trial NCT05649098?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05649098 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Skin Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trem-1 and Ultraviolet Radiation-induced Immune Suppression
ACTIVE NOT RECRUITING · Early Phase 1
-
OCT Vibrography for Biomechanical Properties of Tissues
RECRUITING · NA
-
Effects of Treatments on Atopic Dermatitis
RECRUITING · Phase 2
-
Guselkumab in the Treatment of Adults With Pyoderma Gangrenosum (PG)
RECRUITING · Phase 2
-
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata
RECRUITING · Phase 3
-
Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.